PBS Delisting of Truvada®

From 1 April 2020 **Truvada®** (emtricitabine/tenofovir disoproxil fumarate) for HIV treatment and for pre-exposure prophylaxis (PrEP) will no longer be available through the Pharmaceutical Benefits Scheme (PBS). This involves a decision on delisting of **Truvada®** taken by the Australian Minister and Department of Health under advice from the Pharmaceutical Benefits Advisory Committee (PBAC).

The ASHM Antiretroviral (ARV) Guidelines Committee recommend that patients currently receiving **Truvada®** can transition to other combination medicines that contain tenofovir disoproxil. These are: tenofovir disoproxil fumarate/emtricitabine (Apotex), tenofovir disoproxil maleate/emtricitabine (Mylan), and tenofovir disoproxil phosphate/emtricitabine (Tenofovir EMT GH). This recommendation is for the prevention of acquisition of HIV in pre-exposure prophylaxis (PrEP), and for the treatment of HIV in combination with other antiretrovirals as recommended by the Department of Health and Human Services (DHHS)[1].

1.DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents US Department of Health and Human Services https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0

Locked Bag 5057, Darlinghurst NSW 1300 Australia **T** +61 2 8204 0700 **F** +61 2 9212 2382 **E** ashm@ashm.org.au **W** www.ashm.org.au